TSRO Share Price

Open 118.60 Change Price %
High 119.60 1 Day 0.37 0.31
Low 116.61 1 Week 1.88 1.60
Close 119.04 1 Month -1.36 -1.13
Volume 444133 1 Year 10.45 9.62
52 Week High 192.94
52 Week Low 96.52
TSRO Important Levels
Resistance 2 121.81
Resistance 1 120.67
Pivot 118.42
Support 1 117.41
Support 2 116.27
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
NETE 0.72 44.00%
SCHS 0.04 33.33%
MRGE 0.55 30.95%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
ORIG 24.00 -96.52%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

TESARO, Inc. (NASDAQ: TSRO)

TSRO Technical Analysis 4
As on 22nd Sep 2017 TSRO Share Price closed @ 119.04 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 141.45 & Sell for SHORT-TERM with Stoploss of 123.47 we also expect STOCK to react on Following IMPORTANT LEVELS.
TSRO Target for September
1st Target up-side 142.27
2nd Target up-side 151.47
3rd Target up-side 160.67
1st Target down-side 116.01
2nd Target down-side 106.81
3rd Target down-side 97.61
TSRO Other Details
Segment EQ
Market Capital 430751968.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.tesarobio.com
TSRO Address
TSRO
1000 Winter Street
Suite 3300
Waltham, MA 02451
United States
Phone: 339-970-0900
TSRO Latest News
Interactive Technical Analysis Chart TESARO, Inc. ( TSRO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on TESARO, Inc.
TSRO Business Profile
TESARO, Inc. (TESARO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�s marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). TSR-011 is an orally available anaplastic lymphoma kinase (ALK), inhibitor (targeted anti-cancer agent) is in preclinical development.